Pediatrix director granted 472 restricted shares

Young Sylvia Jean reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Young Sylvia Jean reported acquisition or exercise transactions in this Form 4 filing.

Pediatrix Medical Group, Inc. reported that director Sylvia Jean Young received a grant of 472 restricted shares of common stock on August 12, 2026. The award was granted under the company’s Second Amended and Restated 2008 Incentive Compensation Plan and reflects an increase to her annual equity award. These restricted shares will vest on May 7, 2027, and her directly held common stock position after the grant is 48,286 shares.

Insider Trade Summary

Grant/Award: 472 shares

Grant/Award 1 txn

Insider Young Sylvia Jean

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	472	$26.50	$13K

Holdings After Transaction: Common Stock — 48,286 shares (Direct)

Footnotes (1)

1. F1. Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to the annual equity award. Shares will vest on May 7, 2027.

Key Figures

Restricted shares granted: 472 shares Grant price per share: $26.50 Shares held after transaction: 48,286 shares +1 more

4 metrics

Restricted shares granted 472 shares Grant of restricted common stock on August 12, 2026

Grant price per share $26.50 Reported price per share for the restricted stock award

Shares held after transaction 48,286 shares Total direct common stock holdings following the award

Vesting date May 7, 2027 Date on which the 472 restricted shares will vest

Key Terms

Restricted shares, Incentive Compensation Plan, vest

3 terms

Restricted shares financial

"Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

Incentive Compensation Plan financial

"granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan"

An incentive compensation plan is a formal program that rewards employees and executives with bonuses, stock, or other payments tied to specific performance goals—such as revenue, profit, productivity, or long‑term share price. Investors watch these plans because they shape how leaders make decisions and take risks; like paying a coach by wins rather than effort, well‑designed plans can drive sustainable growth while poor designs can encourage short‑term behaviors that harm shareholder value.

vest financial

"Shares will vest on May 7, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Pediatrix Medical Group (MD) disclose for Sylvia Jean Young?

Pediatrix Medical Group disclosed that director Sylvia Jean Young received a grant of 472 restricted shares of common stock on August 12, 2026. The grant reflects an increase to her annual equity award under the company’s 2008 Incentive Compensation Plan.

At what price were the newly granted Pediatrix (MD) shares recorded?

The 472 restricted shares granted to Sylvia Jean Young were recorded at $26.50 per share. This price is used for reporting purposes on the Form 4 and does not necessarily indicate an open-market purchase or sale transaction.

When do Sylvia Jean Young’s new Pediatrix (MD) restricted shares vest?

The newly granted restricted shares to Sylvia Jean Young will vest on May 7, 2027. Until vesting, they remain subject to the plan’s restrictions and conditions under the Second Amended and Restated 2008 Incentive Compensation Plan.

How many Pediatrix (MD) shares does Sylvia Jean Young hold after this grant?

Following the grant, Sylvia Jean Young directly holds 48,286 shares of Pediatrix Medical Group common stock. This figure includes the newly granted 472 restricted shares reported in the Form 4 filing for August 12, 2026.

Was the Pediatrix (MD) Form 4 transaction made under a Rule 10b5-1 plan?

The filing indicates the Rule 10b5-1 checkbox is not affirmed, and there is no footnote stating use of a trading plan. The reported transaction is an equity award grant rather than an open-market trade under a pre-arranged plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 05:01 PM Accepted by SEC EDGAR 08/14/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Sylvia Jean

(Last) (First) (Middle)

1301 CONCORD TERRACE

(Street)

SUNRISE FLORIDA 33323

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pediatrix Medical Group, Inc. [ MD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2026		A(1)		472	A	$26.5	48,286	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to the annual equity award. Shares will vest on May 7, 2027.

	/s/ David Haddock, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)